Casey Darren P, Conti C Richard, Nichols Wilmer W, Choi Calvin Y, Khuddus Matheen A, Braith Randy W
Center for Exercise Science, Department of Applied Physiology and Kinesiology, College of Health and Human Performance, University of Florida, Gainesville, Florida, USA.
Am J Cardiol. 2008 Feb 1;101(3):300-2. doi: 10.1016/j.amjcard.2007.08.031. Epub 2007 Dec 11.
Cardiovascular disease is associated with chronic low-level inflammation, as evidenced by elevated circulating proinflammatory cytokines. Experimental evidence suggests that inflammation can be suppressed under conditions of high shear stress. This study was conducted to examine the effects of enhanced external counterpulsation (EECP), a noninvasive therapy that increases endothelial shear stress, on circulating levels of inflammatory biomarkers and adhesion molecules in patients with angina pectoris. Twenty-one patients were randomly assigned to either 35 1-hour treatments at cuff pressures of 300 mm Hg (EECP; n=12) or 75 mm Hg (sham; n=9). Plasma tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and soluble vascular cell adhesion molecule-1 were measured before and after 35 1-hour sessions of treatment or sham. Patients in the EECP group demonstrated reductions in tumor necrosis factor-alpha (6.9+/-2.7 vs 4.9+/-2.5 pg/ml, p<0.01; -29%) and monocyte chemoattractant protein-1 (254.9+/-55.9 vs 190.4+/-47.6 pg/ml, p<0.01; -19%) after treatment, whereas there was no change in the sham group. Changes in soluble vascular cell adhesion molecule-1 were not observed in either group. In conclusion, 35 sessions of EECP decreased circulating levels of proinflammatory biomarkers in patients with symptomatic coronary artery disease.
心血管疾病与慢性低度炎症相关,循环促炎细胞因子升高即证明了这一点。实验证据表明,在高剪切应力条件下炎症可得到抑制。本研究旨在探讨增强型体外反搏(EECP)这一增加内皮剪切应力的非侵入性治疗方法,对心绞痛患者循环炎症生物标志物和黏附分子水平的影响。21例患者被随机分为两组,分别接受35次1小时、袖带压力为300 mmHg的治疗(EECP组;n = 12)或袖带压力为75 mmHg的假治疗(假治疗组;n = 9)。在35次1小时的治疗或假治疗前后,检测血浆肿瘤坏死因子-α、单核细胞趋化蛋白-1和可溶性血管细胞黏附分子-1。EECP组患者治疗后肿瘤坏死因子-α(6.9±2.7 vs 4.9±2.5 pg/ml,p<0.01;降低29%)和单核细胞趋化蛋白-1(254.9±55.9 vs 190.4±47.6 pg/ml,p<0.01;降低19%)水平降低,而假治疗组无变化。两组可溶性血管细胞黏附分子-1水平均未观察到变化。总之,35次EECP治疗可降低有症状冠状动脉疾病患者循环促炎生物标志物水平。